Novo Nordisk has lost ground in the weight-loss drug market to Eli Lilly and telehealth companies. The company's new CEO is being far more aggressive, which bodes well. Novo's upcoming Wegovy pill is ...

Novo has experienced a prolonged sell.off over the last months, declining more than 65% from all-time highs. Why some kind of pessimism is justified, the current market cap is way to low considering ...

Millions of people in the world are overweight, and Novo Nordisk hopes to capture a growing share of this lucrative treatment opportunity. A Fool since 2019, and a graduate of Cal State LA with a B.S.

GLP-1 weight loss drugs are still far from cheap, but some of the prices keep dropping. Novo Nordisk is now offering people who pay out of pocket a steep discount for select doses of Ozempic and ...

Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. Boxes for the medications Wegovy and Zepbound are ...

Novo Nordisk A/S shares have declined more than 50% over the past 12 months. Competition in the obesity and type 2 diabetes market and pricing pressure from the U.S. government have weighed on NVO ...

Nov 13 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab denied weight-loss drug partnership with Mangoceuticals (MGRX.O), opens new tab on Thursday, hours after ...

(Bloomberg) --Lars Rebien Sorensen is back as chairman of Novo Nordisk A/S following a shareholder meeting that exposed the depth of rivalry between the Danish drugmaker and US arch nemesis Pfizer Inc ...

Novo Nordisk A/S is tapping the euro bond market with a multi-tranche sale expected to raise about €3.5 billion ($4.1 billion), as the Danish drugmaker seeks funding for its planned purchase of US ...

LONDON, Nov 13 (Reuters) - WeightWatchers' (WW.O), opens new tab CEO said on Wednesday it planned to offer Novo Nordisk's (NOVOb.CO), opens new tab much-anticipated Wegovy in pill form if it is ...

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) climbs about 2% on Monday afternoon after it says it will not raise its offer for Metsera (NASDAQ:MTSR), easing a weeks-long takeover ...